drugset / Trial / NCT00783744

Insulin Glargine Combination Therapies in Type II Diabetics

NCT00783744

Phase 3 Completed 375 enrolled Sanofi
RandomizedParallel-groupOpen-labelTreatment

Summary

To compare efficacy of combination therapy of insulin glargine plus glimepiride and metformin versus 2 injections insulin monotherapy with premixed insulin NPH 30/70 bid in terms of change of HbA1c (baseline to endpoint) to show non-inferiority of insulin glargine plus glimepiride and metformin.

Timeline

Start
2001-12
Primary completion
2003-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Glimepiride Small molecule 3 mg
Subject Glimepiride Small molecule 4 mg
Subject Metformin Small molecule 850 mg
Subject insulin glargine Protein / enzyme biologic
Comparator premixed insulin NPH 30/70 Protein / enzyme biologic